Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNX-2440 in Resectable Liver Metastasis
NCT04714983Phase 1Suspended
- Sponsor
- DNAtrix
- Start
- Feb 2021
- Primary completion
- Jul 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of tezemlimogene daxadenorepvec in liver metastases (3 arms), sponsored by DNAtrix. Primary endpoint: Maximum Tolerated Dose at 1.5 Years. Started Feb 2021; status: suspended.
02
Drugs
tezemlimogene daxadenorepvec
03
Conditions
liver metastases
Beyond the preview
Go deeper on NCT04714983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714983.